4-DMA-7,8-DHF / Eutropoflavin

Eugeroic / energy / focus

Wakefulness, alertness, energy, or focus

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Eugeroic / stimulant / nootropic
Primary mechanism: Catecholamine, wakefulness, or CNS arousal pathways
Primary market use: Eugeroic / energy / focus

Pharmacology

Oral bioavailability: Route-dependent / verify
Half-life: ~3–8 h estimated/prodrug class
Route tags: Route-dependent / verify
Evidence level: Vendor/source-list + secondary signal
Clinical status: Research/reference; verify status
Value-for-money score: 7 / 10

Reported protocol signal

Vendor product-form signal only, not a protocol: 4-DMA-7,8-DHF FREE BASE POWDER (1 GRAM POWDER) | 4-DMA-7,8-DHF FREE BASE POWDER (30 CAPSULES) (10MG/CAPSULE, 300MG TOTAL)

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

Not found in current uploaded master database by normalized name/alias comparison; candidate for review/import.